These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31257689)

  • 21. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies.
    Voshtina E; Szabo A; Hamadani M; Fenske TS; D'Souza A; Chhabra S; Saber W; Drobyski WR; Hari P; Shah NN
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):e33-e38. PubMed ID: 30244105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinic Outcome of Allogeneic Stem Cell Transplantation in 45 Patients with MDS].
    Wang LJ; Liu MJ; Zhao XL; Ding J; Jing Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):502-9. PubMed ID: 27151019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
    Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O'Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA
    Bone Marrow Transplant; 2017 Dec; 52(12):1629-1636. PubMed ID: 28991247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second allogeneic hematopoietic cell transplantation for relapse after first allografts.
    Gyurkocza B; Storb R; Chauncey TR; Maloney DG; Storer BE; Sandmaier BM
    Leuk Lymphoma; 2019 Jul; 60(7):1758-1766. PubMed ID: 30668198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning.
    Townsend WM; Holroyd A; Pearce R; Mackinnon S; Naik P; Goldstone AH; Linch DC; Peggs KS; Thomson KJ; Singer M; Howell DC; Morris EC
    Br J Haematol; 2013 May; 161(4):578-86. PubMed ID: 23496350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates.
    Zhang XH; Xu LP; Liu DH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Wang Y; Zhao T; Chen Y; Fu HX; Liu KY; Huang XJ
    Clin Transplant; 2013; 27(1):80-9. PubMed ID: 22938074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia and Down syndrome.
    Goto H; Kaneko T; Shioda Y; Kajiwara M; Sakashita K; Kitoh T; Hayakawa A; Miki M; Kato K; Ogawa A; Hashii Y; Inukai T; Kato C; Sakamaki H; Yabe H; Suzuki R; Kato K
    Pediatr Blood Cancer; 2015 Jan; 62(1):148-52. PubMed ID: 25262825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
    Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
    Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
    Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission.
    Vignon M; Andreoli A; Dhédin N; Lengliné E; Masson E; Robin M; Granier C; Larghero J; Schlageter MH; de Latour RP; Socié G; Boissel N
    J Adolesc Young Adult Oncol; 2017 Jun; 6(2):299-306. PubMed ID: 27983886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia.
    Mo XD; Tang BL; Zhang XH; Zheng CC; Xu LP; Zhu XY; Wang Y; Liu HL; Yan CH; Chu XD; Chen H; Geng LQ; Liu KY; Sun ZM; Huang XJ
    Int J Cancer; 2016 Nov; 139(9):2106-15. PubMed ID: 27356906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
    Chang YJ; Wang Y; Mo XD; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Chen Y; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Cancer; 2017 Aug; 123(15):2881-2892. PubMed ID: 28301690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
    Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.
    Czerw T; Labopin M; Giebel S; Socié G; Volin L; Fegueux N; Masszi T; Blaise D; Chaganti S; Cornelissen JJ; Passweg J; Maertens J; Itälä-Remes M; Wu D; Mohty M; Nagler A
    Cancer; 2018 Jun; 124(12):2523-2533. PubMed ID: 29603136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation.
    Peffault de Latour R; Calado RT; Busson M; Abrams J; Adoui N; Robin M; Larghero J; Dhedin N; Xhaard A; Clave E; Charron D; Toubert A; Loiseau P; Socié G; Young NS
    Blood; 2012 Oct; 120(16):3353-9. PubMed ID: 22948043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis.
    Stern M; de Wreede LC; Brand R; van Biezen A; Dreger P; Mohty M; de Witte TM; Kröger N; Ruutu T
    Leukemia; 2014 Nov; 28(11):2235-40. PubMed ID: 24781016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.